

UNDERSTANDING THE DISEASE



Understanding hepatic encephalopathy

Nicolas Weiss^{1,2,3*}, Rajiv Jalan⁴ and Dominique Thabut^{1,2,5}

© 2017 Springer-Verlag Berlin Heidelberg and ESICM

Hepatic encephalopathy (HE) is defined as a neurological or a neuropsychological complication caused by liver disease or portosystemic shunting. The clinical spectrum is highly variable ranging from mild neuropsychological disturbances to coma [1]. Depending upon the underlying liver disease, HE is classified into three types: type A, secondary to acute liver failure (ALF); type B, secondary to portosystemic shunting; and type C, secondary to cirrhosis in the presence or not of shunting [2]. The most recent human and animal data confirmed the previously supposed role of hyperammonemia, but also outlines the role of associated factors like inflammation in the development of HE (Fig. 1).

The main source of ammonia (NH_4^+) in the portal system has long been thought to be intestinal bacterial production explaining the use of non-absorbable disaccharides (e.g., lactulose) and non-absorbable antibiotics (e.g., rifaximin) [3]. Recent data shows, however, that the main source is glutamine catabolism by glutaminase in the gut [3]. Thus, polymorphisms in the gene coding for glutaminase predicts the development of HE in cirrhotic patients [4]. In the systemic circulation, NH_4^+ is increased because of reduced urea cycle enzyme activity that occurs in liver failure and/or portosystemic shunting. This increased amount of NH_4^+ is converted to glutamine in muscle cells and in astrocytes, through the action of glutamine synthetase [3, 5]. These aforementioned abnormalities both explain why sarcopenia represents a factor that makes patients susceptible to develop HE in cirrhosis and the development of brain edema in patients with ALF and cirrhosis. Only recently has directly targeting hyperammonemia by using ammonia-lowering agents been

proposed (e.g., glycerol phenylbutyrate, L-ornithine-L-aspartate). According to its osmotic potential, the acute intracytoplasmic increase of glutamine in ALF is responsible for cytotoxic edema affecting the astrocytes and for vasogenic edema when the blood–brain barrier (BBB) is altered [3, 5]. In cirrhosis, the glutamine increase is gradual and astrocytes respond by progressively extruding intracytoplasmic myoinositol and taurine to try and maintain osmotic equilibrium. This largely explains why brain edema is rarely present in cirrhosis and/or in acute-on-chronic liver failure (ACLF) [6, 7]. In neurons, glutamine is deaminated into glutamate, the most important excitatory neurotransmitter in the brain, that stimulates neurons [8]. This could account for anxious behavior, agitation, or seizures in ALF. In contrast, in cirrhosis, compensatory mechanisms are responsible for a decreased expression of both glutamate carriers (GLT-1) and glutamate post-synaptic receptors that explains slowing, sleepiness, and altered consciousness.


Amino acid imbalance has been hypothesized to participate in HE pathophysiology [5, 9]. Cerebral levels of aromatic amino acids (AAA) are increased as a result of altered liver function and increased amount of free tryptophan due to hypoalbuminemia but also to altered transport through the BBB. As a consequence, there is an imbalance in the synthesis of dopamine, norepinephrine, serotonin and the “false neurotransmitters” octopamine or tyramine [3, 5, 8]. Other pathophysiological mechanisms such as cerebral energy failure associated with hyperammonemia, altered immune responses, reduced blood flow, mitochondrial dysfunction, and inhibition of alpha-ketoglutarate dehydrogenase, a rate-limiting tricarboxylic acid cycle enzyme, have been described [9].

Whereas NH_4^+ is not directly correlated with neurological status, several studies demonstrated a good correlation with the presence of systemic inflammatory response syndrome (SIRS) and the blood amount of TNF-alpha or IL-6 [10]. Sepsis and systemic inflammation are a hallmark of the severity of cirrhosis, and infection is a

*Correspondence: nicolas.weiss@aphp.fr

³ Unité de réanimation neurologique, Département de Neurologie, Pôle des Maladies du Système Nerveux, Groupement Hospitalier Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris et Institut de Neurosciences Translationnelles IHU-A-ICM, 47–83 boulevard de l'Hôpital, 75013 Paris, France

Full author information is available at the end of the article



classical triggering event of HE [11]. Outside the field of cirrhosis, encephalopathy related to sepsis has been described. Modification of the intestinal microbiota is emerging as a major factor associated with HE [5, 12]. Its modulation has been proposed to explain the effect of lactulose and rifaximin with conflicting results. More

recently, fecal transplantation has been proposed as a therapeutic strategy in HE. Liver failure is associated with altered intestinal barrier function, which is responsible for bacterial translocation and activation of the innate immune system. Nevertheless, this innate immune response is altered in liver failure as defined by altered

neutrophil phagocytic capacity, reduced reticuloendothelial system, and reduced hepatic synthesis of antimicrobial proteins [13]. ACLF is characterized by upregulation of proinflammatory cytokines (IL-1, IL-6, IL-17, TNF-alpha, IFN-gamma) compared to stable cirrhotic patients [14]. In the brain of HE patients, astrocytes and microglial cells respond to systemic inflammation by producing IL-1beta and IL-6 that stimulate adhesion of neutrophils and their transendothelial migration through the BBB, and the release of chemokines, proteases, and reactive oxygen species [5]. As a result, microglial cells present an activated phenotype. Current data suggest that the brain of patients with cirrhosis are sensitized to the effect of systemic inflammation and infection. Therefore, prompt treatment of any infection is an important therapeutic intervention. Note that anti-inflammatory treatments, i.e., indomethacin or ibuprofen, blocking microglial activation, are able to prevent both neurocognitive symptoms and brain edema in several animal models of HE [10].

Apart from hyperammonemia and inflammation, other factors are suspected to be involved in the physiopathology of HE. Thus, neurotransmission is largely impaired in HE, either as a consequence, as previously discussed for glutamate, dopamine, and serotonin, or as a cause, leading to increased intracerebral levels of benzodiazepine-like compounds or neurosteroids that end in an increased gamma-aminobutyric acid (GABA) tone [8]. The presence of benzodiazepine-like compounds explains why the use of flumazenil had been proposed in the treatment of HE. As a result of liver failure, several substances have been reported in excess in HE patients: phenols, mercaptans, short-chain fatty acids, manganese, and bile acids [9].

Using metabolomics, we recently showed that HE patients displayed several drugs, especially antimicrobial agents (e.g., metronidazole, fluconazole, or beta-lactams), in their CSF [9]. This is in line with clinical studies that could link neurological symptoms with beta-lactams or proton pumps inhibitor intake in cirrhotic patients [15]. Remarkably, these drugs are all substrates of ATP-binding cassette (ABC) transporters expressed on the BBB and responsible for efflux of several drugs outside the brain. We recently showed in HE animal models that ABC transporter expression was altered compared to cirrhotic animals without HE (personal data). These data suggest that some neurological abnormalities could be related to drug-induced encephalopathy. Nevertheless, recent animal data showed that exposure to both bilirubin and bile acids could induce a downregulation of P-glycoprotein (P-gp), the main ABC transporter, on the BBB and that this decreased expression could favor cerebral GABA concentrations. Administration of these

drugs should be carefully considered in cirrhotic patients and considered in the differential diagnosis of brain dysfunction.

Recent progress in cellular biology and immunology has modified our concept of HE physiopathology and will, in the future, provide new treatments.

Author details

¹ Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, Groupement Hospitalier Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris, Paris, France. ² INSERM UMR_S 938CDR Saint-Antoine Maladies Métaboliques, Biliaires et Fibro-Inflammatoire du Foie, Institut de Cardiometabolisme et Nutrition, ICAN, Paris, France. ³ Unité de réanimation neurologique, Département de Neurologie, Pôle des Maladies du Système Nerveux, Groupement Hospitalier Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris et Institut de Neurosciences Translationnelles IHU-A-ICM, 47-83 boulevard de l'Hôpital, 75013 Paris, France. ⁴ Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, London, UK. ⁵ Unité de Soins Intensifs d'Hépatogastroentérologie, Groupement Hospitalier Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris et Université Pierre et Marie Curie Paris 6, Paris, France.

Received: 10 April 2017 Accepted: 13 May 2017

Published online: 25 May 2017

References

- Mouri S, Tripou S, Rudler M et al (2015) Four score, a reliable score for assessing overt hepatic encephalopathy in cirrhotic patients. *Neurocrit Care* 22:251-257
- Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* 35:716-721
- Holecsek M (2015) Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. *Nutrition* 31:14-20
- Romero-Gómez M, Jover M, Del Campo JA et al (2010) Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. *Ann Intern Med* 153:281-288
- Romero-Gómez M, Montagnese S, Jalan R (2015) Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. *J Hepatol* 62:437-447
- Weiss N, Rosselli M, Mouri S et al (2016) Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis. *Metab Brain Dis*. doi:10.1007/s11011-016-9916-9
- Selvapatt N, Singanayagam A, Wendon J, Antoniadis CG (2014) Understanding infection susceptibility in patients with acute-on-chronic liver failure. *Intensive Care Med* 40:1363-1366
- Palomero-Gallagher N, Zilles K (2013) Neurotransmitter receptor alterations in hepatic encephalopathy: a review. *Arch Biochem Biophys* 536:109-121
- Weiss N, Barbier Saint Hilaire P, Colsch B et al (2016) Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy. *J Hepatol* 65:1120-1130
- Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. *J Hepatol* 40:247-254
- Thabut D, Massard J, Gangloff A et al (2007) Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. *Hepatology* 46:1872-1882
- Bajaj JS, O'Leary JG, Reddy KR et al (2012) Second infections independently increase mortality in hospitalized patients with cirrhosis: the North

American consortium for the study of end-stage liver disease (NACSELD) experience. *Hepatology* 56:2328–2335

13. Wasmuth HE, Kunz D, Yagmur E et al (2005) Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. *J Hepatol* 42:195–201
14. Berry PA, Antoniadou CG, Carey I et al (2011) Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. *Intensive Care Med* 37:453–460
15. Weiss N, Junot C, Rudler M et al (2016) Hepatic vs. drug-induced encephalopathy in cirrhotic patients? *Liver Int* 36:1233–1234